APMAdvances in Precision Medicine2424-85922424-9106Bio-Byword Scientific Publishing Pty. Ltd.10.18063/APM.2016.01.005EditorialAdvances in precision medicine — time for a new journalhttps://artdesignp.com/journal/APM/1/1/10.18063/APM.2016.01.005LandeckLilla,HollandRobert L,AsadullahKhusru111970-01-01On January 20, 2015, President Barack Obama announced a major research initiative, “Tonight, I am launching a new personalized medicine initiative to bring us closer to curing diseases like cancer and diabetes and to give all of us access to the personalized information we need to keep ourselves and our families healthier”.[1] The announcement itself indicates commitment and high expectations. Indeed personalized or precision medicine (PM) is presently considered to represent one of the most important trends in medicine.

1. Collins F S and Varmus H, 2015, A new initiative on precision medicine. New England Journal of Medicine, vol.372: 793–795.2. Watson J D and Crick F H, 1953. Molecular structure of nucleic acids. A structure for deoxyribose nucleic acid. Nature, vol.171: 737–738.3. European Union: Strategic Research Agenda for Innovative Medicines Initiative, n.d., accessed December 22, 2015, <http://www.efpia.eu/uploads/Modules/Documents/def_efpia_brochure_sra_a4_web.pdf>4. Biomarkers Definitions Working Group, 2001, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology, vol.69: 89–95.  5. Landeck L, Kneip C, Reischl J, et al. 2015, Biomarkers and personalized medicine: current status and further perspectives with special focus on dermatology, accepted for Experimental Dermatology.6. Table of Pharmacogenomic Biomarkers in Drug Labeling, n.d., accessed 22 December 2015, <http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm>7. Poste G, 2011, Bring on the biomarkers. Nature, vol.469: 156–157.8. Prinz F, Schlange T, Asadullah K, et al. 2011, Believe it nor not — how much can we rely on published data? Nature Reviews Drug Discovery, vol.10: 712.9. Asadullah K, Busch A, Gottwald G, et al. 2015, Industrial–academic collaborations for biomarkers. Nature Reviews Drug Discovery, vol.14: 805–806.  10. Salter H and Holland R, 2014, Biomarkers: refining diagnosis and expediting drug development — reality, aspiration and the role of open innovation. Journal of Internal Medicine, vol. 276: 215–228.